LifeStance Health beats Q3 revenue expectations on clinician growth

LifeStance Health

06/11/2025 11:19

Overview

LifeStance Q3 revenue grows 16% yr/yr, beating analyst expectations

Adjusted EBITDA for Q3 beats estimates, reflecting improved operational efficiency

Company reports net income of $1.1 mln, a turnaround from prior-year loss

Outlook

LifeStance reiterates full-year revenue guidance of $1.41 bln to $1.43 bln

Company raises full-year Adjusted EBITDA expectations to $146 mln to $152 mln

LifeStance expects Q4 revenue between $368 mln and $388 mln

Result Drivers

VISIT VOLUMES - 17% increase in visit volumes driven by clinician growth and productivity improvements

CLINICIAN EXPANSION - Clinician base grew 11% to 7,996, aiding in revenue and visit volume increases

OPERATING LEVERAGE - Improved operating leverage from revenue outpacing G&A expenses, boosting Adjusted EBITDA

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$363.80 mln
$355.60 mln (7 Analysts)
Q3 Net Income
$1.10 mln
Q3 Adjusted EBITDA
Beat
$40.20 mln
$35.16 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for LifeStance Health Group Inc is $8.25, about 41.7% above its November 5 closing price of $4.81

The stock recently traded at 121 times the next 12-month earnings vs. a P/E of 1,965 three months ago

Press Release: ID:nGNX2W5Sdk

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)